Thursday Jul 9
HEALTHOther

Pharma Spends $7B, Approves Zero AI Drugs

7JUL
$7B SPENT0 APPROVED

Finding candidates got cheap and fast. Getting one approved still costs $2.6 billion and years of trials. That gap between the two is where the real money question sits now.

Drugmakers have signed over $7 billion in deals with Insilico Medicine alone since January. Not one of those partnerships has produced an approved medicine yet.

Insilico's lead compound, rentosertib, cleared Phase 2a with positive results, but Phase 2b, Phase 3, and manufacturing review are still ahead. Roughly one in eight candidates ever reaches a patient, and the full path runs about $2.6B.

Software solved the search problem. It hasn't touched the slow part: messy trial data, long timelines, and regulators who still want a human sign-off in the file.

full brief & sources

⚡ Why this matters

  • Reframes AI drug discovery hype: the hard, expensive part was never finding the molecule.
  • $2.6 billion and a 12% success rate are the real numbers that decide if this pays off.
  • More discovery deals mean more candidates competing for the same scarce trial capacity.

🔍 What happened

  • Since January 2026, pharma has committed more than $7 billion to AI-discovery partnerships with Insilico Medicine, covering Servier, Eli Lilly, SK Biopharmaceuticals, and Takeda.
  • Zero AI-discovered drugs have won FDA approval to date.
  • Insilico's rentosertib is the furthest along, with positive Phase 2a results in a peer-reviewed study.
  • Getting one drug from candidate to approval still costs about $2.6 billion.
  • Only about 12% of molecules that enter trials ever reach patients.
  • Clinical trial data across sponsors remains siloed and not model-ready, unlike molecule-design data.

💬 Smart takes

  • Milad Alucozai: "Filters eliminate garbage. They don't create gold" - AI discovery is a better filter, not a way to invent breakthrough biology.
  • Skeptic (Dr. Guy Stephens): Claude Science and similar tools are a step toward regulatory-ready AI, but the FDA still has no pathway for AI output to substitute for investigator judgment.

🧭 Where this goes

  1. Likelymore AI-discovery capital shifts toward trial operations like enrollment and site selection once sponsors feel this bottleneck directly.
  2. Likelyrentosertib's Phase 2b and 3 results become the industry's real test case for the whole category.
  3. Possiblea major sponsor publicly redirects an AI budget from discovery to clinical-ops tooling this year.
  4. Wild Cardthe first AI-discovered drug wins approval within 18 months, resetting the narrative entirely.

🥄 The Spoon Take

The industry just spent $7 billion proving it can build a faster molecule-finding machine. It didn't spend a dollar fixing the slow, siloed, trust-starved system that decides if any of those molecules ever reach a patient. Faster discovery bolted onto a broken pipeline doesn't speed up drugs. It just creates a longer line.

🤔 Pushback

Rentosertib's early Phase 2a data could still fail in Phase 3 like most candidates do, which would undercut the "AI discovery works, execution is the problem" framing entirely.

·Clinical Trial Vanguard - $7B, zero approvals·IntuitionLabs - Lilly-Insilico $2.75B AI drug deal analysis·Artificial Intelligence News - Takeda's $600M Insilico deal